Who should not take Amycretin?
Documented caution flags for Amycretin include mTC / MEN-2 history and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Amycretin is limited.
Documented caution flags for Amycretin
- MTC / MEN-2 history
- Pancreatitis history
- Pregnancy / nursing
Reported side effects to weigh
- Nausea (less than Semaglutide monotherapy in early data)
- Reduced appetite
- Constipation
References
- Amycretin (Novo Nordisk), early Phase 1/2 obesity readouts — Novo Nordisk pipeline, 2024-2025
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Dahl K et al., The Lancet, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human, phase 1 trial — Gasiorek A et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Amycretin
Last updated 2026-06-15.